US equities |
MU $1,035.84 ▼-4.79% NVDA $230.48 ▼-2.94% SNDK $1,609.46 ▼-4.90% AMD $620.68 ▼-3.90% INTC $107.08 ▼-5.34% AAPL $340.42 ▲+1.11% SPCX $160.57 ▼-4.19% META $720.89 ▼-0.06%
FinancialContent

Context Therapeutics Inc. - Common Stock (NQ:CNTX)

0.2990 -0.0110 (-3.55%)
Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Context Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
From Context Therapeutics Inc.
Via GlobeNewswire
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
News headline image
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
From Context Therapeutics Inc.
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
From Context Therapeutics Inc.
Via GlobeNewswire
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Kartoon Studios (NYSE: TOON) Expansion Fuels 2026-2027 Upside – DVLT, UFG, VRME, ARBE More Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
News headline image
CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) Posts Wider Q2 2025 Loss Amid Continued Pipeline Progress ↗
Context Therapeutics reports Q2 2025 loss of $0.09 per share, missing estimates. Pipeline advances with Phase 1 trials for CTIM-76 and CT-95, but shares drop 14.3% post-earnings. Cash runway extends to... 
Via Chartmill
< Previous 1 2 3 4 5 6 7 Next >